2018, Number 1
PDF size: 200.56 Kb.
ABSTRACTIntroduction: Porto-pulmonary hypertension refers to pulmonary arterial hypertension (mean pulmonary artery pressure › 25 mmHg at rest and pulmonary capillary wedge pressure ‹ 15 mmHg) associated with portal hypertension; it is a recognized complication of chronic liver disease. Case report: 85-year-old female with a 3-year course characterized by edema of pelvic limbs, and one month with dry cough, progressive dyspnea and anasarca, on examination: pulmonary basal esters, second pulmonary noise reinforcement. Abdomen with collateral venous network, ascites and anasarca, with oximetry of 84%, electrocardiogram and echocardiography confirmed pulmonary arterial hypertension and abdominal tomography, ascites and dilatation of suprahepatic veins. Managed with diuretics, albumin and phosphodiesterase inhibitors, its evolution was towards clinical and functional improvement. Conclusion: Porto-pulmonary hypertension is an entity with systemic repercussion and poor prognosis, its treatment is still under investigation.
Porres-Aguilar M, Mukherjee D. Portopulmonary hypertension: an update. Respirology. 2015; 20 (2): 235-242.
Porres-Aguilar M, Gallegos-Orozco JF, Garcia H, Aguirre J, Macias-Rodriguez RU, Torre-Delgadillo A. Pulmonary vascular complications in portal hypertension and liver disease: a concise review. Rev Gastroenterol Mex. 2013; 78 (1): 35-44.
Enright PL, Sherril DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998; 158 (5 Pt 1): 1384-1387.
Medarov BI, Chopra A, Judson MA. Clinical aspects of portopulmonary hypertension. Respir Med. 2014; 108 (7): 943-954.
Raevens S, Geerts A, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Colle I. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int. 2015; 35 (6): 1646-1660.
Girerd B, Coulet F, Jaďs X, Eyries M, Van Der Bruggen C, De Man F et al. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. Chest. 2015; 147 (5): 1385-1394.
Porres-Aguilar M, Mukherjee D. Cardiopulmonary hemodynamics for accurate diagnosis of portopulmonary hypertension: a redefinition to consider. Hepatology. 2015; 61 (2): 733-734.
Devaraj A, Loveridge R, Bosanac D, Stefanidis K, Bernal W, Willars C et al. Portopulmonary hypertension: improved detection using CT and echocardiography in combination. Eur Radiol. 2014; 24 (10): 2385-2393.
DuBrock HM, Channick RN, Krowka MJ. What’s new in the treatment of portopulmonary hypertension? Expert Rev Gastroenterol Hepatol. 2015; 9 (7): 983-992.
Martin P, Di Martini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014; 59 (3): 1144-1165.